Colistin use in critically ill patients: In search of the optimal dosing

Chest

Volumn 139, Issue 1, 2011, Pages 234-

  De Pascale, Gennaro ^a   Sandroni, Claudio ^a   Antonelli, Massimo ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIMETHATE; OROSOMUCOID; POLYMYXIN;

ACINETOBACTER BAUMANNII; BACTERIAL STRAIN; CRITICALLY ILL PATIENT; DRUG BINDING; DRUG BLOOD LEVEL; DRUG USE; GRAM NEGATIVE INFECTION; HUMAN; IN VITRO STUDY; LETTER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PSEUDOMONAS AERUGINOSA; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 78651461747     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.10-2031     Document Type: Letter

References (5)

1. Imberti R, Cusato M, Villani P, et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate administration. Chest. 2010;138(6):1333-1339.
2. Bergen PJ, Bulitta JB, Forrest A, Tsuji BT, Li J, Nation RL. Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model. Antimicrob Agents Chemother. 2010;54:3783-3789.
3. Markou N, Markantonis SL, Dimitrakis E, et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Ther. 2008;30(1):143-151.
4. Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother. 2009;53(8):3430-3436.
5. Dudhani RV, Li J, Nation RL. Plasma binding of colistin involves multiple proteins and is concentration dependent: potential clinical implications. In: Program and Abstracts of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12-15, 2009; San Francisco, CA. A1-576.